Navigation Links
Cryoport Expands Logistics Support to Capricor's DYNAMIC Clinical Trial for Heart Failure
Date:4/7/2015

LAKE FOREST, Calif., April 7, 2015 /PRNewswire/ -- Cryoport, Inc. (OTCBB: CYRX) ("Company"), the leading provider of advanced cryogenic logistics solutions for the life sciences industry, serving markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers and reproductive medicine, today announced that the Company has expanded its relationship with Capricor Therapeutics ("Capricor")  to  provide a comprehensive cryogenic logistics solution to support both their ALLSTAR and DYNAMIC clinical trials.

Capricor, based in Los Angeles, California, is a clinical-stage biotechnology company focused on the development and commercialization of innovative therapies to treat cardiovascular diseases. Capricor's lead product candidate, CAP-1002, is an allogeneic, off-the-shelf cell therapy derived from donor heart tissue and infused into a patient's coronary artery. The Company is responsible for the cryogenic logistics that will serve these multi-center trials.

Linda Marbán, Chief Executive Officer of Capricor, commented, "Cryoport has provided valuable cryogenic logistics support for our lead clinical program.  We are grateful for their expertise and their support in a role that is contributing greatly to our progress."

Jerrell Shelton, Chief Executive Officer of Cryoport, stated, "It is our understanding that Capricor's approach to the cardiac space is unique and has potentially great promise in treating cardiovascular disease. We are excited to be able to support the continued progression of Capricor's clinical trial work.  Our best-in-class cryogenic logistics solutions are key components to providing the worldwide access that is required by our clients to successfully conduct their clinical trials. We take very seriously the fact that the Capricor patients enrolled in these trials are dependent on our services that allow them to participate in a program that could potentially lead to the treatment of their disease."

About Cryoport, Inc.
Cryoport is the premier provider of cryogenic logistics solutions to the life sciences industry through its purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. We provide leading edge logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide including points-of-care, CRO's, central laboratories, pharmaceutical companies, contract manufacturers, and university researchers. Our packaging is built around our proprietary Cryoport Express® liquid nitrogen dry vapor shippers, which are validated to maintain a constant -150°C temperature for a 10 day dynamic shipment duration. Our information technology centers around our Cryoportal™ Logistics Management Platform, which facilitates management of the entire shipment process. Cryoport is the preferred cryogenic logistics solutions partner to the world's largest shipping companies controlling more than 85% of the world's air shipments. For more information, visit www.cryoport.com.

To download Cryoport's investor relations app, which offers access to SEC documents, press releases, videos, audiocasts and more, please click to download from your iPhone and iPad or  Android mobile device.

Forward Looking Statements 
Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.'s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, and technical development risks. The company's business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended March 31, 2013. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.


'/>"/>
SOURCE Cryoport, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015
2. Cryoport & UPS Collaborate on Cryogenic Logistics Solutions for the Healthcare Industry
3. Cryoport Increases Revenue by 65% for the First Six Months of Fiscal 2015
4. Cryoport Initiates Support of the Growing In-Vitro Fertilization Market in Nepal
5. Lehigh Valley Expands Fleet of Superbug-Slaying Robots
6. Avillion Expands Leadership Team with Appointment of Ramani Varanasi as Chief Business Officer
7. Fortune 500 Pharmaceutical Company Expands Use of inContact Cloud Contact Center Software Across Multiple Divisions
8. BioDrain Breaks into National Network of Ambulatory Surgical Centers and Expands Installations of its STREAMWAY System throughout the U.S.
9. QIAGEN Expands Pipeline of Promising New Biomarkers for Development of Personalized Healthcare Companion Diagnostics
10. Edison Expands North American Healthcare Sector Coverage With Initiation of Coverage on Bellus Health
11. NextDocs Expands Customer Roster by More Than 10 Percent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and ... financial results for the third quarter of 2017 on ... conference call on that day with the investment community ... The conference call will begin at 9 ... can access a live webcast of the conference call ...
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation announce a ... sensors for real-time monitoring of patients with trauma-related and ... focused on disruptive health solutions for rare disorders and ... record and integrate behavioral, cognitive, physiological and contextual data. ... ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
Breaking Medicine Technology:
(Date:10/13/2017)... Pekin, IL (PRWEB) , ... October 13, 2017 ... ... Foundation, which established the certification process to promote standards of excellence for the ... iaedp™ Symposium, scheduled for March 22 – 25, 2018 in Orlando, Florida at ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... will be giving viewers the lowdown on sciatica in a new episode of ... that focuses on current events and innovation and investigates each subject in-depth with ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
(Date:10/12/2017)... ... ... Asante, a nationally recognized health system in southern Oregon, ... health joint venture through an agreement, effective October 1, 2017, to create AccentCare ... company with Asante, delivering clinically integrated care, for the past eight years. This ...
Breaking Medicine News(10 mins):